Multicentre Trials

The following table provides a list of the multicentre trials using the NCRI PET Core Lab to provide site accreditation and quality control procedures for the PET component of the study. For more details on an individual study please click on the trial name to view more details. Whilst we try to keep information about the trials up-to-date, this information should only be used as a guide and the trial co-ordinator for the study should be contacted directly for further information on the trial.


Trial Name Tumour Type Title Phase Status
ABLE
Lung An Open Label Multi Centre Preoperative Window of Opportunity Study of Afatinib in Stage Ia to IIb Non Small Cell Lung Cancer Phase II Completed
ANIMATE
Hodgkin Lymphoma A phase II study of nivolumab monotherapy in patients with relapsed/refractory Hodgkin lymphoma, fit for autologous stem cell transplant, who fail to reach complete metabolic remission after first or second line salvage therapy Phase II In set-up
AZD3965
Adult Solid Tumour, Diffuse Large B Cell Lymphoma, Burkitt Lymphoma A Phase I Trial of AZD3965 in Patients With Advanced Cancer Phase I Open
BACCHUS
Rectal A phase II Multicentre Open-label Randomised Study of Neoadjuvant Chemotherapy and Bevacizumab in Patients with MRI defined High-Risk Cancer of the Rectum Phase II Closed
BREVITY
Lymphoma A phase II study of brentuximab vedotin using a response adapted design in patients with Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or co-morbidity Phase II In follow-up
CARDAMON
Multiple Myeloma Carfilzomib/Cyclophosphamide/Dexamethasone with maintenance carfilzomib in untreated transplant-eligible patients with symptomatic MM to evaluate the benefit of upfront ASCT Phase II Open
CHEMO-T
Lymphoma Cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) versus gemcitabine, cisplatin and methyl prednisolone (GEM-P) in the first line treatment of T-cell Lymphoma, a multicentre randomised phase II study Phase II In follow-up
EURONET_PHL_C2
Hodgkin Lymphoma Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents Open
FALCON
Prostate A phase 3, open-label study to assess the clinical utility of Fluciclovine (F-18) PET/CT in patients with prostate cancer with biochemical recurrence after radical treatment Phase III In follow-up
FGFR Study
Gastro-oesophageal, Breast, Lung Proof-of-concept study of AZD4547 in patients with FGFR1 or FGFR2 amplified tumours Phase II In follow-up
IELSG-37
Lymphoma A randomized, open label, multicentre, two-arm phase III comparative study assessing the role of mediastinal radiotherapy after rituximab containing chemotherapy regimens to patients with newly diagnosed Primary Mediastinal Large B-Cell Lymphoma (PMLBCL) Phase III Open
LEGEND
Lymphoma A randomised phase II study comparing LEnalidomide plus rituximab, GEmcitabine and methylprednisolone (LR-GEM) to rituximab, gemcitabine, methylprednisolone and cisplatiN (RG-EMP) in second-line treatment of Diffuse Large B-cell lymphoma (DLBCL) Phase II In follow-up
MAPPING
Cervix, Endometrium Diagnostic accuracy of MRI, diffusion-weighted MRI, FDGPET/CT and Fluoro-ethyl-choline PET/CT in the detection of lymph node metastases in surgically staged endometrial and cervical carcinoma Phase II In follow-up
PAIReD
Hodgkin Lymphoma Phase II study of reduced intensity allogeneic transplantation for refractory Hodgkin lymphoma Phase II In follow-up
PET after 2 cycles in NHL (R-CHOP 14vs21 PET sub-study)
Lymphoma Blinded evaluation of prognostic value of FDG-PET after 2 cycles of chemotherapy in Diffuse Large B-cell Non-Hodgkin's Lymphoma N/A In follow-up
PET-PANC
Pancreas The impact of combined modality positron emission tomography with computerised tomography scanning (PET/CT) in the diagnosis and management of pancreatic cancer Phase II In follow-up
PETReA
Follicula Lymphoma PETReA: Phase 3 evaluation of PET-guided, Response-Adapted therapy in patients with previously untreated, high tumour burden follicular lymphoma Phase III Open
POETIC: FLT-PET sub-study
Breast Trial of Perioperative Endocrine Therapy - Individualising Care: FLT-PET sub-study Phase III In follow-up
RAPID
Lymphoma A Randomised Phase III Trial to Determine the Role of FDG-PET Imaging in Clinical Stages IA/IIA Hodgkins Disease Phase III In follow-up
RATHL
Hodgkin Lymphoma A randomised Phase III trial to assess response adapted therapy using FDG-PET imaging in patients with newly diagnosed, advanced Hodgkin Lymphoma Phase III In follow-up
REASURE
Prostate A phase 2 open-label study of biomarkers to assess response in patients with metastatic castration resistant prostate cancer treated with radium-223 Phase II In follow-up
ReBeL
Follicular Lymphoma ReBeL study: a randomized phase I/II trial of lenalidomide and rituximab with or without bendamustine in patients >= 18 years with relapsed follicular lymphoma. A HOVON/GLSG/NCRI study Phase I/II Open
SCOPE 2
Oesophogeal A randomised Phase II/III trial to study radiotherapy dose escalation in patients with oesophageal cancer treated with definitive chemo-radiation with an embedded Phase II trial for patients with a poor early response using positron emission tomography (PET) Phase II/III Open
SPUtNIk
Lung Solitary Pulmonary Unidentified Nodule Investigation: Accuracy and Cost-Effectiveness of Dynamic Contrast Enhanced Computed Tomography in the Characterisation of Solitary Pulmonary Nodules N/A In follow-up
STO3 PET Sub-study
Stomach A Randomised Phase II/III trial of Perioperative Chemotherapy with or without Bevacizumab in Operable Oesophagogastric Adenocarcinoma and (in selected centres) A Feasibility Study Evaluating Lapatinib in HER-2 Positive Oesophagogastric Adenocarcinomas. FDG-PET Sub-study Phase II/III In follow-up
TITAN
Head & Neck Randomised controlled open-label trial of TPF induction chemotherapy in the surgical management of locally advanced head and neck cancer Phase II/III Closed
TORCH
Diffuse Large BCell Lymphoma A phase II study to determine the safety and efficacy of the dual mTORC inhibitor AZD2014 and to investigate additional toxicities in combination with rituximab in relapsed refractory DLBCL Phase II In follow-up

Back to top